Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines.
Identifieur interne : 005307 ( Main/Exploration ); précédent : 005306; suivant : 005308Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines.
Auteurs : Yuxian He [États-Unis] ; Yusen Zhou ; Hao Wu ; Baojun Luo ; Jingming Chen ; Wanbo Li ; Shibo JiangSource :
- Journal of immunology (Baltimore, Md. : 1950) [ 0022-1767 ] ; 2004.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (sang), Biologie informatique (), Cartographie épitopique (), Données de séquences moléculaires, Fragments peptidiques (administration et posologie), Fragments peptidiques (immunologie), Fragments peptidiques (synthèse chimique), Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (administration et posologie), Glycoprotéines membranaires (immunologie), Glycoprotéines membranaires (synthèse chimique), Humains, Lapins, Protéines de l'enveloppe virale (administration et posologie), Protéines de l'enveloppe virale (immunologie), Protéines de l'enveloppe virale (synthèse chimique), Protéines recombinantes (administration et posologie), Protéines recombinantes (immunologie), Protéines recombinantes (synthèse chimique), Souris, Souris de lignée BALB C, Structure tertiaire des protéines (génétique), Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (diagnostic), Syndrome respiratoire aigu sévère (immunologie), Séquence d'acides aminés, Trousses de réactifs pour diagnostic, Vaccins antiviraux (administration et posologie), Vaccins antiviraux (immunologie), Vaccins antiviraux (synthèse chimique), Vaccins inactivés (administration et posologie), Vaccins inactivés (immunologie), Vaccins inactivés (synthèse chimique), Virus du SRAS (génétique), Virus du SRAS (immunologie), Épitopes immunodominants (administration et posologie), Épitopes immunodominants (analyse), Épitopes immunodominants (immunologie).
- MESH :
- administration et posologie : Fragments peptidiques, Glycoprotéines membranaires, Protéines de l'enveloppe virale, Protéines recombinantes, Vaccins antiviraux, Vaccins inactivés, Épitopes immunodominants.
- analyse : Épitopes immunodominants.
- diagnostic : Syndrome respiratoire aigu sévère.
- génétique : Structure tertiaire des protéines, Virus du SRAS.
- immunologie : Fragments peptidiques, Glycoprotéines membranaires, Protéines de l'enveloppe virale, Protéines recombinantes, Syndrome respiratoire aigu sévère, Vaccins antiviraux, Vaccins inactivés, Virus du SRAS, Épitopes immunodominants.
- sang : Anticorps antiviraux.
- synthèse chimique : Fragments peptidiques, Glycoprotéines membranaires, Protéines de l'enveloppe virale, Protéines recombinantes, Vaccins antiviraux, Vaccins inactivés.
- Animaux, Biologie informatique, Cartographie épitopique, Données de séquences moléculaires, Glycoprotéine de spicule des coronavirus, Humains, Lapins, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère, Séquence d'acides aminés, Trousses de réactifs pour diagnostic.
English descriptors
- KwdEn :
- Amino Acid Sequence, Animals, Antibodies, Viral (blood), Computational Biology (methods), Epitope Mapping (methods), Humans, Immunodominant Epitopes (administration & dosage), Immunodominant Epitopes (analysis), Immunodominant Epitopes (immunology), Membrane Glycoproteins (administration & dosage), Membrane Glycoproteins (chemical synthesis), Membrane Glycoproteins (immunology), Mice, Mice, Inbred BALB C, Molecular Sequence Data, Peptide Fragments (administration & dosage), Peptide Fragments (chemical synthesis), Peptide Fragments (immunology), Protein Structure, Tertiary (genetics), Rabbits, Reagent Kits, Diagnostic, Recombinant Proteins (administration & dosage), Recombinant Proteins (chemical synthesis), Recombinant Proteins (immunology), SARS Virus (genetics), SARS Virus (immunology), Severe Acute Respiratory Syndrome (diagnosis), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Spike Glycoprotein, Coronavirus, Vaccines, Inactivated (administration & dosage), Vaccines, Inactivated (chemical synthesis), Vaccines, Inactivated (immunology), Viral Envelope Proteins (administration & dosage), Viral Envelope Proteins (chemical synthesis), Viral Envelope Proteins (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (chemical synthesis), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Immunodominant Epitopes, Membrane Glycoproteins, Peptide Fragments, Recombinant Proteins, Vaccines, Inactivated, Viral Envelope Proteins, Viral Vaccines.
- chemical , analysis : Immunodominant Epitopes.
- chemical , blood : Antibodies, Viral.
- chemical , chemical synthesis : Membrane Glycoproteins, Peptide Fragments, Recombinant Proteins, Vaccines, Inactivated, Viral Envelope Proteins, Viral Vaccines.
- chemical , immunology : Immunodominant Epitopes, Membrane Glycoproteins, Peptide Fragments, Recombinant Proteins, Vaccines, Inactivated, Viral Envelope Proteins, Viral Vaccines.
- diagnosis : Severe Acute Respiratory Syndrome.
- genetics : Protein Structure, Tertiary, SARS Virus.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- methods : Computational Biology, Epitope Mapping.
- prevention & control : Severe Acute Respiratory Syndrome.
- Amino Acid Sequence, Animals, Humans, Mice, Mice, Inbred BALB C, Molecular Sequence Data, Rabbits, Reagent Kits, Diagnostic, Spike Glycoprotein, Coronavirus.
Abstract
The spike (S) protein of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) is not only responsible for receptor binding and virus fusion, but also a major Ag among the SARS-CoV proteins that induces protective Ab responses. In this study, we showed that the S protein of SARS-CoV is highly immunogenic during infection and immunizations, and contains five linear immunodominant sites (sites I to V) as determined by Pepscan analysis with a set of synthetic peptides overlapping the entire S protein sequence against the convalescent sera from SARS patients and antisera from small animals immunized with inactivated SARS-CoV. Site IV located in the middle region of the S protein (residues 528-635) is a major immunodominant epitope. The synthetic peptide S(603-634), which overlaps the site IV sequence reacted with all the convalescent sera from 42 SARS patient, but none of the 30 serum samples from healthy blood donors, suggesting its potential application as an Ag for developing SARS diagnostics. This study also provides information useful for designing SARS vaccines and understanding the SARS pathogenesis.
DOI: 10.4049/jimmunol.173.6.4050
PubMed: 15356154
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002B69
- to stream PubMed, to step Curation: 002B69
- to stream PubMed, to step Checkpoint: 002C62
- to stream Ncbi, to step Merge: 000A58
- to stream Ncbi, to step Curation: 000A58
- to stream Ncbi, to step Checkpoint: 000A58
- to stream Main, to step Merge: 005719
- to stream Main, to step Curation: 005307
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines.</title><author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name><affiliation wicri:level="2"><nlm:affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name></author><author><name sortKey="Wu, Hao" sort="Wu, Hao" uniqKey="Wu H" first="Hao" last="Wu">Hao Wu</name></author><author><name sortKey="Luo, Baojun" sort="Luo, Baojun" uniqKey="Luo B" first="Baojun" last="Luo">Baojun Luo</name></author><author><name sortKey="Chen, Jingming" sort="Chen, Jingming" uniqKey="Chen J" first="Jingming" last="Chen">Jingming Chen</name></author><author><name sortKey="Li, Wanbo" sort="Li, Wanbo" uniqKey="Li W" first="Wanbo" last="Li">Wanbo Li</name></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15356154</idno><idno type="pmid">15356154</idno><idno type="doi">10.4049/jimmunol.173.6.4050</idno><idno type="wicri:Area/PubMed/Corpus">002B69</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002B69</idno><idno type="wicri:Area/PubMed/Curation">002B69</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002B69</idno><idno type="wicri:Area/PubMed/Checkpoint">002C62</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002C62</idno><idno type="wicri:Area/Ncbi/Merge">000A58</idno><idno type="wicri:Area/Ncbi/Curation">000A58</idno><idno type="wicri:Area/Ncbi/Checkpoint">000A58</idno><idno type="wicri:doubleKey">0022-1767:2004:He Y:identification:of:immunodominant</idno><idno type="wicri:Area/Main/Merge">005719</idno><idno type="wicri:Area/Main/Curation">005307</idno><idno type="wicri:Area/Main/Exploration">005307</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines.</title><author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name><affiliation wicri:level="2"><nlm:affiliation>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name></author><author><name sortKey="Wu, Hao" sort="Wu, Hao" uniqKey="Wu H" first="Hao" last="Wu">Hao Wu</name></author><author><name sortKey="Luo, Baojun" sort="Luo, Baojun" uniqKey="Luo B" first="Baojun" last="Luo">Baojun Luo</name></author><author><name sortKey="Chen, Jingming" sort="Chen, Jingming" uniqKey="Chen J" first="Jingming" last="Chen">Jingming Chen</name></author><author><name sortKey="Li, Wanbo" sort="Li, Wanbo" uniqKey="Li W" first="Wanbo" last="Li">Wanbo Li</name></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name></author></analytic><series><title level="j">Journal of immunology (Baltimore, Md. : 1950)</title><idno type="ISSN">0022-1767</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term><term>Animals</term><term>Antibodies, Viral (blood)</term><term>Computational Biology (methods)</term><term>Epitope Mapping (methods)</term><term>Humans</term><term>Immunodominant Epitopes (administration & dosage)</term><term>Immunodominant Epitopes (analysis)</term><term>Immunodominant Epitopes (immunology)</term><term>Membrane Glycoproteins (administration & dosage)</term><term>Membrane Glycoproteins (chemical synthesis)</term><term>Membrane Glycoproteins (immunology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Molecular Sequence Data</term><term>Peptide Fragments (administration & dosage)</term><term>Peptide Fragments (chemical synthesis)</term><term>Peptide Fragments (immunology)</term><term>Protein Structure, Tertiary (genetics)</term><term>Rabbits</term><term>Reagent Kits, Diagnostic</term><term>Recombinant Proteins (administration & dosage)</term><term>Recombinant Proteins (chemical synthesis)</term><term>Recombinant Proteins (immunology)</term><term>SARS Virus (genetics)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (diagnosis)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccines, Inactivated (administration & dosage)</term><term>Vaccines, Inactivated (chemical synthesis)</term><term>Vaccines, Inactivated (immunology)</term><term>Viral Envelope Proteins (administration & dosage)</term><term>Viral Envelope Proteins (chemical synthesis)</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (chemical synthesis)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux (sang)</term><term>Biologie informatique ()</term><term>Cartographie épitopique ()</term><term>Données de séquences moléculaires</term><term>Fragments peptidiques (administration et posologie)</term><term>Fragments peptidiques (immunologie)</term><term>Fragments peptidiques (synthèse chimique)</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (administration et posologie)</term><term>Glycoprotéines membranaires (immunologie)</term><term>Glycoprotéines membranaires (synthèse chimique)</term><term>Humains</term><term>Lapins</term><term>Protéines de l'enveloppe virale (administration et posologie)</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Protéines de l'enveloppe virale (synthèse chimique)</term><term>Protéines recombinantes (administration et posologie)</term><term>Protéines recombinantes (immunologie)</term><term>Protéines recombinantes (synthèse chimique)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Structure tertiaire des protéines (génétique)</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (diagnostic)</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Séquence d'acides aminés</term><term>Trousses de réactifs pour diagnostic</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins antiviraux (synthèse chimique)</term><term>Vaccins inactivés (administration et posologie)</term><term>Vaccins inactivés (immunologie)</term><term>Vaccins inactivés (synthèse chimique)</term><term>Virus du SRAS (génétique)</term><term>Virus du SRAS (immunologie)</term><term>Épitopes immunodominants (administration et posologie)</term><term>Épitopes immunodominants (analyse)</term><term>Épitopes immunodominants (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Immunodominant Epitopes</term><term>Membrane Glycoproteins</term><term>Peptide Fragments</term><term>Recombinant Proteins</term><term>Vaccines, Inactivated</term><term>Viral Envelope Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Immunodominant Epitopes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Membrane Glycoproteins</term><term>Peptide Fragments</term><term>Recombinant Proteins</term><term>Vaccines, Inactivated</term><term>Viral Envelope Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Immunodominant Epitopes</term><term>Membrane Glycoproteins</term><term>Peptide Fragments</term><term>Recombinant Proteins</term><term>Vaccines, Inactivated</term><term>Viral Envelope Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Fragments peptidiques</term><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Protéines recombinantes</term><term>Vaccins antiviraux</term><term>Vaccins inactivés</term><term>Épitopes immunodominants</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Épitopes immunodominants</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Protein Structure, Tertiary</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Structure tertiaire des protéines</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Fragments peptidiques</term><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Protéines recombinantes</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Vaccins inactivés</term><term>Virus du SRAS</term><term>Épitopes immunodominants</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Computational Biology</term><term>Epitope Mapping</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Fragments peptidiques</term><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Protéines recombinantes</term><term>Vaccins antiviraux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term><term>Animals</term><term>Humans</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Molecular Sequence Data</term><term>Rabbits</term><term>Reagent Kits, Diagnostic</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Biologie informatique</term><term>Cartographie épitopique</term><term>Données de séquences moléculaires</term><term>Glycoprotéine de spicule des coronavirus</term><term>Humains</term><term>Lapins</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère</term><term>Séquence d'acides aminés</term><term>Trousses de réactifs pour diagnostic</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The spike (S) protein of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) is not only responsible for receptor binding and virus fusion, but also a major Ag among the SARS-CoV proteins that induces protective Ab responses. In this study, we showed that the S protein of SARS-CoV is highly immunogenic during infection and immunizations, and contains five linear immunodominant sites (sites I to V) as determined by Pepscan analysis with a set of synthetic peptides overlapping the entire S protein sequence against the convalescent sera from SARS patients and antisera from small animals immunized with inactivated SARS-CoV. Site IV located in the middle region of the S protein (residues 528-635) is a major immunodominant epitope. The synthetic peptide S(603-634), which overlaps the site IV sequence reacted with all the convalescent sera from 42 SARS patient, but none of the 30 serum samples from healthy blood donors, suggesting its potential application as an Ag for developing SARS diagnostics. This study also provides information useful for designing SARS vaccines and understanding the SARS pathogenesis.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><noCountry><name sortKey="Chen, Jingming" sort="Chen, Jingming" uniqKey="Chen J" first="Jingming" last="Chen">Jingming Chen</name><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name><name sortKey="Li, Wanbo" sort="Li, Wanbo" uniqKey="Li W" first="Wanbo" last="Li">Wanbo Li</name><name sortKey="Luo, Baojun" sort="Luo, Baojun" uniqKey="Luo B" first="Baojun" last="Luo">Baojun Luo</name><name sortKey="Wu, Hao" sort="Wu, Hao" uniqKey="Wu H" first="Hao" last="Wu">Hao Wu</name><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name></noCountry><country name="États-Unis"><region name="État de New York"><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005307 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005307 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:15356154
|texte= Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:15356154" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |